Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b/4 trial of ciraparantag (PER 977) as an investigational anticoagulant reversal agent

Trial Profile

A Phase 3b/4 trial of ciraparantag (PER 977) as an investigational anticoagulant reversal agent

Status: Planning
Phase of Trial: Phase III/IV

Latest Information Update: 11 Aug 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciraparantag (Primary)
  • Indications Haemorrhage
  • Focus Registrational; Therapeutic Use
  • Sponsors AMAG Pharmaceuticals; Perosphere
  • Most Recent Events

    • 06 Aug 2020 According to an AMAG Pharmaceuticals media release, Phase 3 clinical program of Ciraparantag (AMAG-977) would be conducted to support regulatory approval of ciraparantag by the U.S. Food and Drug Administration, the European Medicines Agency, and the Medicines and Healthcare Products Regulatory Agency.
    • 17 Jan 2019 According to an AMAG Pharmaceuticals media release, company has completed the acquisition of Perosphere Pharmaceuticals.
    • 17 Jan 2019 According to an AMAG Pharmaceuticals media release, the company has completed the previously announced acquisition of Perosphere Pharmaceuticals Inc.Through this acquisition, AMAG adds ciraparantag to its development portfolio.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top